PepGen's core business segment revolves around the development of innovative therapies for neuromuscular diseases, with a primary focus on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company employs its proprietary Enhanced Delivery Oligonucleotide (EDO) platform to create targeted oligonucleotide therapeutics. Research and development efforts are concentrated on advancing clinical programs such as PGN-EDO51 for DMD and PGN-EDODM1 for DM1. These therapies aim to improve patient outcomes by addressing the underlying genetic causes of these debilitating conditions. PepGen's market positioning is strengthened by its novel EDO technology, which enhances the delivery and efficacy of oligonucleotide drugs. Future opportunities include expanding the pipeline to address other neuromuscular disorders and securing regulatory approvals for its lead product candidates. The company actively engages in clinical trials to validate the safety and efficacy of its therapies, with a focus on demonstrating meaningful improvements in muscle function and quality of life for patients.